Select a medication above to begin.
Enhertu (fam-trastuzumab deruxtecan-nxki)
fam-trastuzumab deruxtecan
Black Box Warnings .
Interstitial Lung Dz
incl. fatal cases have occurred; monitor for new or worsening respiratory s/sx incl. cough, dyspnea, fever; permanently D/C tx if Grade 2 or higher interstitial lung dz or pneumonitis occurs; advise pts of risk and to immediately report any sx
Embryo-Fetal Toxicity
exposure during pregnancy can result in embryo-fetal harm; advise pts of risks and need for effective contraception
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = fam-trastuzumab deruxtecan-nxki; not interchangeable w/ ado-trastuzumab emtansine or other trastuzumab-containing products
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
breast CA, unresectable or metastatic
- [HER2-positive dz]
- Dose: 5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for pts who have received a prior anti-HER2-based regimen
- [HER2-low dz]
- Dose: 5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for pts w/ IHC1+ or IHC2+/ISH-negative dz who have received prior tx
- [hormone receptor-positive HER2-low dz]
- Dose: 5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for pts w/ IHC1+ or IHC2+/ISH-negative dz who have progressed on prior endocrine-based tx
- [hormone receptor-positive HER2-ultralow dz]
- Dose: 5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for pts w/ IHC0 w/ membrane staining dz who have progressed on prior endocrine-based tx
HER2-mutant non-small cell lung CA, unresectable or metastatic
- [5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle]
- Info: for pts w/ activating HER2 (ERBB2) mutations who have received prior tx
HER2-positive gastric CA, locally advanced or metastatic
- [6.4 mg/kg/dose IV x1 on day 1 of 21-day cycle]
- Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen
HER2-positive solid tumors, unresectable or metastatic
- [5.4 mg/kg/dose IV x1 on day 1 of 21-day cycle]
- Info: for pts w/ IHC3+ dz who have received prior tx and have no alternative tx options
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- avoid: breastfeeding during tx and x7mo after D/C
- caution: pts of childbearing potential
- caution: male pts of reproductive potential
- caution: CrCl <60
- caution: bilirubin >1.5x ULN
Drug Interactions .
Overview
fam-trastuzumab deruxtecan
HER2-directed ADC
- cardiotoxic effects
- myelosuppressive oncologic agent
Avoid/Use Alternative
- ado-trastuzumab emtansine
- chloramphenicol
- cladribine oral
- deferiprone
- dexrazoxane
- doxorubicin
- epirubicin
- fam-trastuzumab deruxtecan
- fexinidazole
- ganciclovir
- idarubicin
- palifermin
- penicillamine
- primaquine
- radium Ra 223 dichloride
- ropeginterferon alfa-2b
- trastuzumab
- valganciclovir
Monitor/Modify Tx
- adalimumab
- albendazole
- aldesleukin
- alemtuzumab
- allopurinol
- alogliptin
- anagrelide
- anti-thymocyte globulin
- asciminib
- asenapine
- atidarsagene autotemcel
- auranofin
- avelumab
- axitinib
- azathioprine
- balsalazide
- baricitinib
- benznidazole
- betibeglogene autotemcel
- bevacizumab
- bezlotoxumab
- binimetinib
- bortezomib
- bosutinib
- capecitabine
- carfilzomib
- certolizumab pegol
- cidofovir
- cilostazol
- clozapine
- cobimetinib
- colchicine
- cyclophosphamide
- dabrafenib
- dapsone
- daunorubicin
- deferasirox
- deuruxolitinib
- dronedarone
- efbemalenograstim alfa
- eflapegrastim (G-CSF)
- elivaldogene autotemcel
- encorafenib
- entrectinib
- etanercept
- everolimus
- exagamglogene autotemcel
- filgrastim (G-CSF)
- flucytosine
- fluorouracil
- fluphenazine
- foscarnet
- fostamatinib
- givinostat
- golimumab
- hydroxychloroquine
- hydroxyurea
- ibrutinib
- ifosfamide
- iloperidone
- imatinib
- infliximab
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- itraconazole
- lapatinib
- leflunomide
- lenvatinib
- linagliptin
- linezolid
- lonafarnib
- lovotibeglogene autotemcel
- lumateperone
- lymphocyte immune globulin, anti-thymocyte globulin
- margetuximab
- mavacamten
- mercaptopurine
- mesalamine
- mesalamine rectal
- methotrexate
- mirdametinib
- mitoxantrone
- mobocertinib
- mycophenolate mofetil
- mycophenolic acid
- olsalazine
- osimertinib
- pazopanib
- pegfilgrastim (G-CSF)
- peginterferon alfa 2a
- peginterferon beta 1a
- pentamidine
- pertuzumab
- pioglitazone
- ponatinib
- proguanil
- propafenone
- pyrimethamine
- ribavirin
- rifabutin
- ripretinib
- rituximab
- rosiglitazone
- ruxolitinib topical
- sargramostim (GM-CSF)
- sarilumab
- satralizumab
- saxagliptin
- selumetinib
- sirolimus
- sitagliptin
- sorafenib
- stiripentol
- succimer
- sulfasalazine
- sunitinib
- teplizumab
- teriflunomide
- thalidomide
- tivozanib
- tocilizumab
- tofacitinib
- trabectedin
- trametinib
- trimethoprim
- upadacitinib
- valproic acid
- vandetanib
- zanidatamab
- zenocutuzumab
- zidovudine
Adverse Reactions .
Serious Reactions
- interstitial lung dz
- pneumonitis
- pneumonia
- pleural effusion
- dyspnea
- neutropenia
- febrile neutropenia
- infection, serious
- anemia
- thrombocytopenia
- lymphopenia
- hemorrhage
- left ventricular dysfxn
- hypokalemia
- peripheral neuropathy
- intestinal obstruction
- edema
Common Reactions
- nausea
- fatigue
- alopecia
- vomiting
- constipation
- appetite decr.
- diarrhea
- anemia
- musculoskeletal pain
- abdominal pain
- headache
- stomatitis
- cough
- interstitial lung dz
- respiratory infection
- weight decr.
- rash
- dizziness
- dyspepsia
- dyspnea
- epistaxis
- fever
- dysgeusia
- COVID-19
- pruritus
- edema
- peripheral neuropathy
- dry eyes
- blurred vision
- skin hyperpigmentation
- hemorrhage
- dehydration
- abdominal distension
- neutrophils decr.
- lymphocytes decr.
- Plt decr.
- ALT or AST incr.
- alk phos incr.
- potassium decr.
Safety/Monitoring .
Monitoring Parameters
pregnancy test at baseline; CBC w/ diff at baseline, prior to each dose, and as clinically indicated; LVEF at baseline, then at regular intervals as clinically indicated; s/sx interstitial lung dz
Look/Sound-Alike Drug Names
fam-trastuzumab deruxtecan confused with: trastuzumab, ado-trastuzumab emtansine
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human data available, though risk of oligohydramnios and oligohydramnios sequence based on limited human data w/ trastuzumab
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x7mo after D/C in pts of childbearing potential and during tx and x4mo after D/C in male pts
Lactation
Clinical Summary
avoid breastfeeding during tx and x7mo after D/C; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for fam-trastuzumab deruxtecan: catabolism; CYP450: unknown; Info: antibody-drug conjugate releases active drug deruxtecan; for deruxtecan: unknown; CYP450: 3A4 substrate
Excretion: unknown; Half-life: 5.7-5.8 days (fam-trastuzumab deruxtecan), 5.5-5.8 days (unconjugated deruxtecan)
Subclass: HER2 Antagonists ; Immunotherapy, Antibody-Drug Conjugates ; Immunotherapy, HER2 Inhibitors ; Mitosis Inhibitors, Topoisomerase I Inhibitors
Mechanism of Action
binds to HER2-expressing cells, forming internalized complex which releases deruxtecan intracellularly; deruxtecan binds to topoisomerase I-DNA complexes, causing DNA damage and apoptosis (antibody-drug conjugate)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.